LusterM, AktolunC, AmendoeiraI, BarczynskiM, BibleKC, DuntasLH, EliseiR, Handkiewicz-JunakD, HoffmannM, JarzabB, LeenhardtL, MusholtTJ, NewboldK, NixonIJ, SmitJ, Sobrinho-SimoesM, SosaJA, TuttleRM, VerburgFA, WartofskyL, FuhrerD. 2019. European perspective on 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: proceedings of an interactive international symposium. Thyroid, 29:7–26.
2.
HaugenBR, AlexanderEK, BibleKC, DohertyGM, MandelSJ, NikiforovYE, PaciniF, RandolphGW, SawkaAM, SchlumbergerM, SchuffKG, ShermanSI, SosaJA, StewardDL, TuttleRM, WartofskyL. 2016. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid, 26:1–133.
3.
MiddletonWD, TeefeySA, ReadingCC, LangerJE, BelandMD, SzabunioMM, DesserTS. 2018. Comparison of performance characteristics of American College of Radiology TI-RADS, Korean Society of Thyroid Radiology TIRADS, and American Thyroid Association guidelines. AJR Am J Roentgenol, 210:1148–1154.
4.
CostanteG, DuranteC, FrancisZ, SchlumbergerM, FilettiS. 2009. Determination of calcitonin levels in C-cell disease: clinical interest and potential pitfalls. Nat Clin Pract Endocrinol Metab, 5:35–44.
5.
SnyderJ, GormanC, ScanlonP. 1983. Thyroid remnant ablation: questionable pursuit of an ill-defined goal. J Nucl Med, 24:659–665.
6.
Van NostrandD. 2018. Radioiodine refractory differentiated thyroid cancer: time to update the classifications. Thyroid, 28:1083–1093.
7.
DeandreisD, RubinoC, TalaH, LeboulleuxS, TerroirM, BaudinE, LarsonS, FaginJA, SchlumbergerM, TuttleRM. 2017. Comparison of empiric versus whole-body/-blood clearance dosimetry-based approach to radioactive iodine treatment in patients with metastases from differentiated thyroid cancer. J Nucl Med, 58:717–722.
8.
KluijfhoutWP, PasternakJD, DrakeFT, BeninatoT, ShenWT, GosnellJE, Suh IC L, DuhQY. 2017. Application of the new American Thyroid Association guidelines leads to a substantial rate of completion total thyroidectomy to enable adjuvant radioactive iodine. Surgery, 161:127–133.
9.
HayID, GrantCS, TaylorWF, McConaheyWM. 1987. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery, 102:1088–1095.
10.
VickeryAL Jr, WangCA, WalkerAM. 1987. Treatment of intrathyroidal papillary carcinoma of the thyroid. Cancer, 60:2587–2595.
11.
AdamMA, ThomasS, YoungwirthL, HyslopT, ReedSD, ScheriRP, RomanSA, SosaJA. 2017. Is there a minimum number of thyroidectomies a surgeon should perform to optimize patient outcomes?. Ann Surg, 265:402–407.
12.
VerburgFA, GiovanellaL, IakovouI, KonijnenbergMW, LangstegerW, LassmannM, MihailovicJ, LusterM. 2018. I-131 as adjuvant treatment for differentiated thyroid carcinoma may cause an increase in the incidence of secondary haematological malignancies: an “inconvenient” truth?. Eur J Nucl Med Mol Imaging, 45:2247–2249.
13.
VerburgFA, LusterM, GiovanellaL. 2017. Adjuvant post-operative I-131 therapy in differentiated thyroid carcinoma: are the 2015 ATA guidelines an exact science or a dark art?. Eur J Nucl Med Mol Imaging, 44:183–184.
14.
BeierwaltesWH, RabbaniR, DmuchowskiC, LloydRV, EyreP, MalletteS. 1984. An analysis of “ablation of thyroid remnants” with I-131 in 511 patients from 1947–1984: experience at University of Michigan. J Nucl Med, 25:1287–1293.
15.
SissonJC. 1983. Applying the radioactive eraser: I-131 to ablate normal thyroid tissue in patients from whom thyroid cancer has been resected. J Nucl Med, 24:743–745.
16.
DobynsBM, MaloofF. 1951. The study and treatment of 119 cases of carcinoma of the thyroid with radioactive iodine. J Clin Endocrinol Metab, 11:1323–1360.
HayID, BergstralhEJ, GoellnerJR, EbersoldJR, GrantCS. 1993. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery, 114:1050–1057; discussion 1057–1058.
19.
MazzaferriEL, YoungRL, OertelJE, KemmererWT, PageCP. 1977. Papillary thyroid carcinoma: the impact of therapy in 576 patients. Medicine (Baltimore), 56:171–196.
20.
MazzaferriEL, YoungRL. 1981. Papillary thyroid carcinoma: a 10 year follow-up report of the impact of therapy in 576 patients. Am J Med, 70:511–518.
IyerNG, MorrisLG, TuttleRM, ShahaAR, GanlyI. 2011. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer, 117:4439–4446.
23.
SawkaAM, ThabaneL, ParleaL, Ibrahim-ZadaI, TsangRW, BrierleyJD, StrausS, EzzatS, GoldsteinDP. 2009. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid, 19:451–457.
24.
BoucaiL, FalconeJ, UkenaJ, CoombsCC, ZehirA, PtashkinR, BergerMF, LevineRL, FaginJA. 2018. Radioactive iodine-related clonal hematopoiesis in thyroid cancer is common and associated with decreased survival. J Clin Endocrinol Metab, 103:4216–4223.
25.
ParkKW, WuJX, DuL, LeungAM, YehMW, LivhitsMJ. 2018. Decreasing use of radioactive iodine for low-risk thyroid cancer in California, 1999 to 2015. J Clin Endocrinol Metab, 103:1095–1101.
26.
PaciniF, SchlumbergerM, DralleH, EliseiR, SmitJW, Wiersinga W; European Thyroid CancerTaskforce. 2006. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol, 154:787–803.
27.
ItoY, MiyauchiA, OdaH. 2018. Low-risk papillary microcarcinoma of the thyroid: a review of active surveillance trials. Eur J Surg Oncol, 44:307–315.
28.
LusterM, ClarkeSE, DietleinM, LassmannM, LindP, OyenWJ, TennvallJ, BombardieriE, European Association of NuclearM. 2008. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging, 35:1941–1959.
29.
VerburgFA, AktolunC, ChitiA, FrangosS, GiovanellaL, HoffmannM, IakovouI, MihailovicJ, KrauseBJ, LangstegerW, LusterM, Eanm, theETC. 2016. Why the European Association of Nuclear Medicine has declined to endorse the 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Eur J Nucl Med Mol Imaging, 43:1001–1005.
30.
VaismanF, TalaH, GrewalR, TuttleRM. 2011. In differentiated thyroid cancer, an incomplete structural response to therapy is associated with significantly worse clinical outcomes than only an incomplete thyroglobulin response. Thyroid, 21:1317–1322.
31.
RobenshtokE, NachalonY, BenbassatC, HirschD, ShimonI, GrossmanA, Diker-CohenT, AkirovA, PopovtzerA. 2017. Disease severity at presentation in patients with disease-related mortality from differentiated thyroid cancer: implications for the 2015 ATA guidelines. Thyroid, 27:1171–1176.
